|
 |
|
|
|
|
7Scheme 2012 |
|
Modules and tests
in previous years (2006-2011) |
|
Scheme 2011 |
|
General module |
|
|
|
Events |
Run 31 |
Run 32 |
Run 33 |
|
Epitopes
to be detected
(click on underlined markers for
description)
|
CD30,
CD56,
CD68 (or
CD163),
CGA,
MLA |
CD31,
CK-HMW,
EpCAM
MSH6,
MUM1 |
CK-LMW,
CALR,
CyD1,
CDX2,
TTF1
|
Breast cancer module |
|
Events |
Run B11 |
Run B12 |
|
Epitopes
to be detected
(click on underlined markers for
description)
|
- |
ER,
HER-2 IHC*,
HER-2 BRISH** |
PR,
HER-2 IHC*,
HER-2 BRISH** |
|
* Labs not performing HER-2 IHC may substitute with PR
in run B11 and ER
in run B12
** BRISH comprises CISH and SISH (but not FISH).
Abbreviations: BRISH: Brightfield in situ
hybridisation; CISH: Chromogene in situ
hybridisation; ER: Estrogen receptor; IHC: Immunohistochemistry; PR:
Progesterone receptor; SISH: Silver in situ hybridisation. |
|
Gastric
cancer pilot module 2011
Module for gastric/GEJ cancer HER2 IHC, comprises 2 runs in 2011: G1
together with run 31 and G2 together with run 33.
The module opened only for NordiQC labs required to carry out
these tests for the purpose of trastuzumab therapy for gastric/GEJ
cancer. When
submitting the protocol, the name and e-mail address of a
responsible oncologist must be indicated in the Comments' field. The number of
participating labs in the pilot module is limited to 50. The
assessments are carried out in collaboration with Targos Molecular
Pathology GmbH und Pathologie in Kassel, Germany. The pilot module
is sponsored by Roche, participation is free for NordiQC labs.
Limited participation - fully
booked for 2011 |
|
Events |
Run G1 |
|
Run G2 |
|
Epitope
to be detected
|
HER-2 IHC |
- |
HER-2 IHC |
|
Scheme 2010 |
|
General module |
|
Events |
Run 28 |
Run 29 |
Run 30 |
|
Epitopes
to be detected
(click on underlined markers for
description)
|
BCL2,
BCL6,
BSAP,
CD99,
EMA,
WT1 |
CA125, CD4,
CD79a,
CK19,
SYP |
CD34,
CK-PAN,
IgM,
MLH1,
VIM |
|
Abbreviations: BSAP: B-cell specific activator
protein, PAX-5; CA125: Cancer antigen 125; CK: Cytokeratin; EMA:
Epithelial membrane antigen; SYP: Synaptophysin; VIM: Vimentin; WT1:
Wilms' tumor-1. |
Breast cancer module |
|
Events |
Run B9 |
Run B10 |
|
Epitopes
to be detected
(click on underlined markers for
description)
|
- |
PR,
HER-2 IHC*,
HER-2 BRISH** |
ER,
HER-2 IHC*,
HER-2 BRISH** |
|
* Labs not performing HER-2 IHC may substitute with ER
in run B9 and PR in run B10.
** BRISH comprises CISH and SISH (but not FISH).
Abbreviations: BRISH: Brightfield in situ
hybridisation; CISH: Chromogene in situ
hybridisation; ER: Estrogen receptor; IHC: Immunohistochemistry; PR:
Progesterone receptor; SISH: Silver in situ hybridisation. |
|
|
|
Scheme 2009 |
|
General module |
|
Events |
Run 25 |
Run 26 |
Run 27 |
|
Epitopes
to be detected1)
(click on underlined markers for
description)
|
CD15,
CD30,
CK7,
CK20,
CK-LMW,
GCDFP/MAMGLO* |
AMACR/PIN-cocktail*
CD31,
CD68,
CD117,
p16 |
ASMA,
CD10,
CDX2,
CEA,
PSA/Prostein* |
|
* Choose ONE of the two markers
indicated
Abbreviations: AMACR: alpha-methylacyl-CoA racemase,
(P504S protein); ASMA: alpha-smooth muscle
antigen; CDX2: Caudal related homeobox-2; CEA: Carcinoembryonic
antigen; HCALD: H-Caldesmon; CK: Cytokeratin; CK-LMW:
Cytokeratin, low molecular weight (the Ab should detect at least one primary/constitutive CK of simple epithelia, i.e., CK8 or CK18);
GCDFP: Gross cystic disease fluid protein-15 (select this OR
Mammaglobin); MAMGLO: Mammaglobin (select this
OR GCDFP);
PIN: Prostate intraepithelial neoplasia - cocktail, e.g. CK5/p63/AMACR; PSA: Prostate specific
antigen. |
Breast cancer module |
|
Events |
Run B7
/ pilot C1 |
Run B8
/ pilot C2 |
|
Epitopes
to be detected1)
|
ER,
HER-2*,
Ki67 |
ER,
HER-2*,
SMH/p63** |
|
* B7/B8:
HER-2 IHC, C1/C2: HER-2 CISH/SISH; ** Choose ONE of the two markers
indicated
|
|
Abbreviations: ER: Estrogen receptor; SMH:
Smooth muscle heavy chain myosin (e.g., clone SMMS1). |
|
|
|
Scheme 2008 |
|
General module |
|
Events |
Run 22 |
Run 23 |
Run 24 |
|
Epitopes
to be detected
|
CD3,
CD15,
CDX2,
CGA,
MSH2,
SYP |
CR,
Ep-CAM,
IgK,
IgM,
TTF-1 |
CD5,
CD23,
CK-Pan,
MLA,
OCT3/4,
PLAP |
|
Abbreviations: CDX2: Caudal related homeobox-2; CK-Pan: Pan- or broad spectrum cytokeratin (the Ab should detect at
least one primary/constitutive CK of simple epithelia, i.e., CK8 or
CK18, and one primary/constitutive CK of squamous epithelia,
i.e., CK5 or CK14); CGA: Chromogranin A; CR: Calretinin; Ep-CAM:
Epithelial cell-cell adhesion molecule (e.g., Ber-EP4 or MOC31);
IgK: Immunoglobulin kappa; IgM: Immunoglobulin M; MLA: Melan A;
MSH2: Mut-S homologue; 2OCT3/4: Octamer transcription factor 3/4;
PLAP: Placental alkaline phosphatase; SYP: Synaptophysin; TTF-1: Thyroid
transcription factor-1. |
|
Breast module |
|
Events |
Run B5 |
Run B6 |
|
Epitopes
to be detected
|
ECAD,
ER,
HER-21) |
CK-HMW,
HER-21),
PR |
|
Abbreviations: CK-HMW: Cytokeratin
high
molecular weight
(the Ab should detect at least one primary/constitutive
CK of of squamous epithelia,
i.e., CK5 or CK14); ECAD: E-cadherin; ER: Estrogen receptor; PR: Progesterone receptor |
|
|
Scheme 2007 |
|
General module |
|
Events |
Run 19 |
Run 20 |
Run 21 |
|
Epitopes
to be detected1)
(click for updated monographs)
|
CD23,
CR,
CyD1,
Ki67,
Podop,
TTF1, |
CK-LMW,
CK-Pan,
MLA,
MSA,
p53, S100 |
ASMA,
CD20,
CD79a,
CD117,
CD138,
DES |
|
Abbreviations: ASMA: alpha-smooth muscle
antigen; CK-LMW:
Cytokeratin, low molecular weight (the Ab should detect at least one primary/constitutive CK of simple epithelia, i.e., CK8 or CK18);
CK-Pan: Pan- or broad spectrum cytokeratin (the Ab should detect at
least one primary/constitutive CK of simple epithelia, i.e., CK8 or
CK18, and one primary/constitutive CK of squamous epithelia,
i.e., CK5 or CK14); CR: Calretinin;
CyD1: cyclin D1; DES: desmin; MLA: Melan A; MSA: melanosoma specific
antigen (HMB-45); Podop: podoplanin = D2-40; TTF1: thyroid
transcription factor-1. |
Breast module |
|
Events |
Run B3 |
Run B4 |
|
Epitopes
to be detected1)
|
ER,
HER-21) |
HER-21),
PR |
|
1) If a laboratory is unable to stain for HER-2, it can be
replaced by PR in Run B3 and ER in Run B4. Use the field "Other
epitope" in the protocol form. |
|
Abbreviations: ER: Estrogen receptor, PR
Progesterone receptor |
|
Scheme
2006
|
|
General module |
|
Events |
Run 16 |
Run 17 |
Run 18 |
|
Epitopes to be detected1)
(click for updated monographs)
|
AMACR,
CD10,
CK-LMW,
CK-HMW,
MLA,
p63 |
ALK,
bcl-6,
CD5,
CR,
CyD1,
Ep-CAM |
CGA,
IgK,
IgM,
NFP,
Syp,
TdT |
|
Abbreviations: ALK: Anaplastic lymphoma kinase,
AMACR: alpha-methylacyl-CoA racemase, (P504S protein), CGA:
chromogranin A, CK-HMW: Cytokeratin, high molecular weight (the Ab
should detect at least one primary/constitutive CK of
complex/stratified epithelia, ie., CK5 or CK14), CK-LMW: Cytokeratin,
low molecular weight (the Ab should detect at least one
primary/constitutive CK of simple epithelia, i.e., CK8 or CK18), CR:
Calretinin, CyD1: Cyclin D1, Ep-CAM: Epithelial cellular adhesion
molecule (Abs., e.g., Ber-EP4 or MOC-31); IgK: Immunoglobulin Kappa;
IgM: Immunoglobulin M; NFP: Neurofilament protein, Syp: Synaptophysin,
TdT: Terminal deoxynucleotidyl transferase. |
Breast module |
|
|
|
|
Events |
Run B1 |
Run B2 |
|
Epitopes to be detected1)
|
HER-21),
ER |
HER-21),
PgR |
|
1) If a laboratory is unable to stain for HER-2, it can be
replaced by PgR in Run B1 and ER in Run B2. Use the field "Other
epitope" in the protocol form. |
|
Abbreviations: ER: Estrogen receptor, PgR
Progesterone receptor |
|
| MV/AS |
|
Last
update
28-12-2011 |
|